

Maria Albanese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4843532/publications.pdf>

Version: 2024-02-01

58
papers

1,333
citations

361296

20
h-index

377752

34
g-index

61
all docs

61
docs citations

61
times ranked

2067
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3â€­month observational, longitudinal, cohort, multicenter, Italian realâ€­life study. <i>European Journal of Neurology</i> , 2022, 29, 1198-1208.	1.7	43
2	Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study. <i>Brain Sciences</i> , 2022, 12, 154.	1.1	31
3	Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1228.	1.0	11
4	Effects of Ultramicrosized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Caseâ€­Control Study. <i>Pharmaceuticals</i> , 2022, 15, 253.	1.7	13
5	Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). <i>Journal of Headache and Pain</i> , 2022, 23, 46.	2.5	46
6	Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience. <i>Journal of Neurology</i> , 2022, 269, 5848-5857.	1.8	17
7	Medication overuse and drug addiction: a narrative review from addiction perspective. <i>Journal of Headache and Pain</i> , 2021, 22, 32.	2.5	36
8	Narrative Medicine to integrate patientsâ€™™, caregiversâ€™™ and cliniciansâ€™™ migraine experiences: the DRONE multicentre project. <i>Neurological Sciences</i> , 2021, 42, 5277-5288.	0.9	14
9	Ultramicrosized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. <i>Pharmaceuticals</i> , 2021, 14, 336.	1.7	21
10	Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). <i>Journal of Headache and Pain</i> , 2021, 22, 35.	2.5	82
11	Fampridine improves acute optic neuritis contributing to a long-lasting recovery of nerve function. <i>Neurological Sciences</i> , 2021, 42, 4833-4836.	0.9	2
12	Choriocapillaris Integrity in Relapsed Central Serous Chorioretinopathy in a Patient Treated With Fingolimod for Multiple Sclerosis: New Insights From Optical Coherence Tomography Angiography. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, e51-e53.	0.4	3
13	Complex Rearrangement of the Entire Retinal Posterior Pole in Patients with Relapsing Remitting Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4693.	1.0	2
14	Fremanezumab in the prevention of high-frequency episodic and chronic migraine: Friend (fremanezumab in real world study), the first Italian multicenter, prospective real-life study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119272.	0.3	0
15	Long-term (>48 weeks) safety and tolerability of erenumab in real-life. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119287.	0.3	0
16	Distortion Product Otoacoustic Emissions and Their Suppression as Predictors of Peripheral Auditory Damage in Migraine: A Case-Control Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5007.	1.0	5
17	Functional Assessment of Outer and Middle Macular Layers in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3766.	1.0	7
18	Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). <i>Neurological Sciences</i> , 2020, 41, 487-488.	0.9	14

#	ARTICLE	IF	CITATIONS
19	Morphological Outer Retina Findings in Multiple Sclerosis Patients With or Without Optic Neuritis. <i>Frontiers in Neurology</i> , 2020, 11, 858.	1.1	6
20	Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. <i>Haematologica</i> , 2020, 105, 2056-2070.	1.7	70
21	Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. <i>Journal of Headache and Pain</i> , 2020, 21, 55.	2.5	37
22	Treatment with Dimethyl Fumarate Enhances Cholinergic Transmission in Multiple Sclerosis. <i>CNS Drugs</i> , 2019, 33, 1133-1139.	2.7	7
23	Feasibility of automated detection of sleep apnea using implantable pacemakers and defibrillators: a comparison with simultaneous polysomnography recording. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 56, 327-333.	0.6	11
24	Subclinical cochlear dysfunction in newly diagnosed relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 55-60.	0.9	13
25	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 636-641.	1.8	28
26	Abnormal cervical lymph nodes in multiple sclerosis: a preliminary ultrasound study. <i>Radiologia Medica</i> , 2018, 123, 202-208.	4.7	5
27	No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. <i>Neurology</i> , 2017, 88, 1144-1152.	1.5	57
28	Facial diplegia resembling bilateral Ramsay Hunt Syndrome. <i>Journal of the Neurological Sciences</i> , 2017, 376, 109-111.	0.3	5
29	TRPV1 polymorphisms and risk of interferon β -induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017, 305, 172-174.	1.1	5
30	Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study. <i>PLoS ONE</i> , 2017, 12, e0165415.	1.1	5
31	Heart rate variability in untreated newly diagnosed temporal lobe epilepsy: Evidence for ictal sympathetic dysregulation. <i>Epilepsia</i> , 2016, 57, 418-426.	2.6	45
32	Modulation of monocytes by bioactive lipid anandamide in multiple sclerosis involves distinct Toll-like receptors. <i>Pharmacological Research</i> , 2016, 113, 313-319.	3.1	22
33	Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. <i>Journal of Neuroinflammation</i> , 2016, 13, 36.	3.1	54
34	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. <i>Sleep Medicine</i> , 2016, 21, 140-144.	0.8	55
35	Lower instantaneous entropy of heartbeat dynamics during seizures in untreated temporal lobe epilepsy. , 2015, , .		1
36	Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system?. <i>Sleep Medicine</i> , 2015, 16, 1071-1076.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Oral l-carnitine as treatment for narcolepsy without cataplexy during pregnancy: A case report. <i>Journal of the Neurological Sciences</i> , 2015, 348, 282-283.	0.3	9
38	Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldt-Jakob disease. <i>Journal of the Neurological Sciences</i> , 2015, 348, 274-276.	0.3	9
39	Restless legs syndrome and post polio syndrome: a case-control study. <i>European Journal of Neurology</i> , 2015, 22, 472-478.	1.7	15
40	Nocturnal frontal lobe epilepsy with paroxysmal arousals due to CHRNA2 loss of function. <i>Neurology</i> , 2015, 84, 1520-1528.	1.5	32
41	Refractory restless legs syndrome remitting after dual kidney transplantation. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 81-83.	1.1	2
42	Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. <i>Neurology</i> , 2014, 82, 1752-1753.	1.5	20
43	CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?. <i>Journal of Sleep Research</i> , 2014, 23, 420-424.	1.7	37
44	Effects of epilepsy treatment on sleep architecture and daytime sleepiness: An evidence-based review of objective sleep metrics. <i>Epilepsia</i> , 2014, 55, 777-778.	2.6	3
45	Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and self-reported questionnaires. <i>European Journal of Neurology</i> , 2014, 21, 929-934.	1.7	37
46	Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. <i>Neurology</i> , 2014, 83, 572-573.	1.5	4
47	Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis. <i>Epilepsia & Behavior Case Reports</i> , 2014, 2, 161-163.	1.5	2
48	Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. <i>JAMA Neurology</i> , 2014, 71, 1498.	4.5	262
49	May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy?. <i>Sleep Medicine</i> , 2014, 15, 1424.	0.8	7
50	Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. <i>Journal of Neurology</i> , 2014, 261, 1832-1836.	1.8	25
51	Sleep disorders in spinal and bulbar muscular atrophy (Kennedy's disease): a controlled polysomnographic and self-reported questionnaires study. <i>Journal of Neurology</i> , 2014, 261, 889-893.	1.8	21
52	Multiple sleep latency test may be not sensitive in obstructive sleep apnea with comorbid narcolepsy revealed by low cerebrospinal fluid orexin levels. <i>Sleep Medicine</i> , 2014, 15, 1171.	0.8	2
53	Epstein-Barr virus neuraxis infection as a trigger for central nervous system demyelinating processes: a case report. <i>Multiple Sclerosis Journal</i> , 2013, 19, 380-381.	1.4	3
54	Increased cortical excitability after selective REM sleep deprivation in healthy humans: A transcranial magnetic stimulation study. <i>Sleep Medicine</i> , 2013, 14, 288-292.	0.8	42

#	ARTICLE	IF	CITATIONS
55	Unilateral spatial neglect and alien limb phenomenon may be early features of Creutzfeldtâ€“Jakob disease. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 379-381.	1.1	4
56	Electroencephalography and Dementia: A Literature Review and Future Perspectives. <i>CNS and Neurological Disorders - Drug Targets</i> , 2013, 12, 512-519.	0.8	6
57	Spasticity as an ictal pattern due to excitotoxic upper motor neuron damage. <i>Epilepsy and Behavior</i> , 2012, 25, 397-400.	0.9	1
58	Pure ictal sensory seizures may represent a clinical manifestation of PLEDs. <i>Epilepsy and Behavior</i> , 2012, 23, 509.	0.9	4